University of the Incarnate Word
847 E Hildebrand Ave
San Antonio, TX 78212
Biofest Invest is an annual spring event that brings together potential investors from across the nation and Texas bioscience companies seeking investment funding, while sharing best practices, connections, and valuable advice. The day-long event includes relevant speakers and panelists on valuable topics relevant to bioscience companies. Organizations that provide support to bioscience entrepreneurs will also be on-site to provide information.
On Wednesday, April 17th from 10:15 - 11:00 am partner Eva Yin will be speaking on the panel “New Federal Changes Affecting Startups,” and partner Robert Suffoletta, along with Darius Dills from the firm’s Austin office, will be in attendance holding 1:1 office hours.
Katie Stonum
kstonum@wsgr.comEva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
Rob works with emerging growth and technology companies, both public and private, as well as investment banks and venture capital funds.
Darius Dills is a corporate associate in the Austin office of Wilson Sonsini Goodrich & Rosati, where he represents start-ups and emerging growth companies from incorporation through exit. His experience includes advising emerging and growth-stage businesses on strategic transactions, including mergers and acquisitions, and on corporate legal issues, venture capital, and venture debt financings. He also represents investors in venture capital financings, mergers and acquisitions, and capital markets transactions. Darius has particular experience working with clients in the life sciences, consumer products, medical device, software and aviation sectors.